🔗 Share this article

While the US continues making historic adjustments to its immunization schedules, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by casting doubt on Covid vaccinations during the pandemic and has zeroed in on potential deaths following COVID-19 immunization in her recent position at the FDA.

Proposed Changes to Pediatric Vaccine Program

Agency leaders were set to announce radical changes to the childhood vaccination calendar in December, synchronizing the US with the Danish national calendar, according to reports – a substantial departure that would place the US out of alignment with many the world with little proof for public health gain. The planned update has been postponed until the new year.

In place of the top vaccines chief, Dr. Høeg is listed to address the audience at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment could signify a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

The new acting director has often pushed for ending some pediatric immunization guidelines in the US in order to be more in line with Denmark's approach, a country with nationalized medicine and a citizenry roughly the size of the state of Wisconsin.

So far statements, she has persisted in emphasizing on vaccination policy – usually the purview of Dr. Prasad, chief of the FDA’s CBER – rather than drug regulation.

Concerns Over Background

Dr. Høeg has no apparent track record in pharmaceutical research, regulation or management, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the CDER, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in managing a large organization. She is not an expert in pharmaceutical oversight.”

Previous commissioners of the center would “understand regulatory frameworks and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who headed CBER have had.”

The drug center has an enormous workload at the FDA, Woodcock pointed out.

“Everybody just focuses on the novel medication approvals, but the generic program clears numerous generic medications. There’s a biosimilars division, OTC medication office and more, and each of these must be looked after,” she noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major management component to the job, which oversees over 5,000 personnel. “It is a huge management job, if you execute it properly,” she concluded.

Agency Reaction and Disputed Programs

In response to concerns about Høeg’s qualifications and whether this selection signifies increased cooperation among FDA leaders on immunizations, a representative said that the “inquiries stem from flawed assumptions”.

“Her experience is consistent with the functions of her role,” the official stated, citing the period Dr. Høeg spent advising the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a disputed rapid therapy clearance system that reportedly worried her predecessors. “How are these medications being selected for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he stated, “the FDA looks to be trending towards less stringent regulations of all drugs, except for immunizations.”

Documented History on Immunizations

With immunizations, Dr. Høeg has a clearer, if problematic, history, critics said. She authored a study using unverified volunteer-provided data to determine the frequency of heart inflammation following Covid immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the current government featured altering rules for novel immunizations and ending “unnecessary” vaccines, she remarked after the election on a audio program. At the agency, Dr. Høeg has according to sources floated the idea of barring young men from obtaining COVID-19 vaccines.

“She’s an all-around dogmatist who begins with her preconceived notions and reverse-engineers to retrofit the data in a extremely misleading, fraudulent way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with fellow contrarians, {like|